Clinical Evaluation of a Time-Sequential Biphasic NMN–Resveratrol–Quercetin–Piperine NAD+ Supplement Targeting SIRT1 (BCLC™)
Frontiers in Sustainable Development · 22.04.2026 · 6 (4) · 1-9
DOI: 10.54691/7pt02z87 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Sustainable Development, online erschienen am 22.04.2026. Verfasst von Nour-Eddine Ziraoui und 2 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Time-sequential biphasic NAD+ formulations are designed to solve the temporal mismatch, poor dissolution, and exposure instability that often limit conventional NMN combinations. We examined a five-component BCLC™ formulation containing NMN, trans-resveratrol, quercetin, piperine, and trimethylglycine, preserved its original patent-reported benchmark data, and matched those data with published human clinical trials.
Methods
We retained the original formulation specifications, dissolution and stability results, and in-vitro SIRT1-related benchmarks reported in the source document, then searched PubMed, PubMed Central, and clinical-trial records through March 28, 2026 for adult interventional studies involving NMN, resveratrol, quercetin, or piperine that were relevant to NAD+, SIRT1, insulin sensitivity, oxidative stress, physical function, or bioavailability.
Results
In the patent dataset, the leading embodiments achieved 4.1–5.5-fold SIRT1 pathway activation, 95.6–98.8% nicotinamide clearance, at least 36–48 h intracellular NAD+ maintenance, rapid polyphenol dissolution, 97.8–98.5% three-month retention, and material loss no higher than 3.5%. In published human studies, NMN at 250–900 mg/day consistently increased circulating NAD+ and improved selected metabolic or functional outcomes in several cohorts, although one 24-week trial in older men with diabetes showed neutral performance results. Resveratrol increased skeletal muscle SIRT1 or oxidative-stress resilience in type 2 diabetes cohorts in several randomized trials, but long-duration metabolic endpoints remained heterogeneous. Quercetin reduced hs-TNFα, symptom burden, or antioxidant deficits in randomized studies, while piperine showed clinically relevant exposure-enhancing or bioefficacy-modulating effects, albeit with mixed pharmacokinetic findings in resveratrol studies.
Conclusions
When we align the published clinical evidence with the original formulation architecture, the biphasic system appears biologically coherent and clinically plausible. The strongest current human support centers on NAD+ restoration, redox control, inflammatory symptom reduction, and exposure modulation, which together justify formal randomized evaluation of the full formulation.
Zitieren
APA
Ziraoui, N., Rossi, S., & Volkov, D. (2026). Clinical Evaluation of a Time-Sequential Biphasic NMN–Resveratrol–Quercetin–Piperine NAD+ Supplement Targeting SIRT1 (BCLC™). Frontiers in Sustainable Development, 6(4), 1-9. https://doi.org/10.54691/7pt02z87
Vancouver
Ziraoui N, Rossi S, Volkov D. Clinical Evaluation of a Time-Sequential Biphasic NMN–Resveratrol–Quercetin–Piperine NAD+ Supplement Targeting SIRT1 (BCLC™). Frontiers in Sustainable Development. 2026;6(4):1-9. doi:10.54691/7pt02z87
BibTeX
@article{Ziraoui2026,
author = {Ziraoui, Nour-Eddine and Rossi, Sofia and Volkov, Dmitri},
title = {Clinical Evaluation of a Time-Sequential Biphasic NMN–Resveratrol–Quercetin–Piperine NAD+ Supplement Targeting SIRT1 (BCLC™)},
journal = {Frontiers in Sustainable Development},
year = {2026},
volume = {6},
number = {4},
pages = {1--9},
doi = {10.54691/7pt02z87}
}
EUVIMED